Live Breaking News & Updates on Pd Research Laboratory

Share this article
Share this article
NEW YORK, Feb. 9, 2021 /PRNewswire/ Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ( Alterity or the Company ) has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson s disease (PD) based on imaging of brain iron.
The funding for US$495,000 will be used to evaluate the pharmacologic profile of ATH434 in a primate model to determine the optimal dose of ATH434 in future Parkinson s disease clinical trials.  This is the second grant that Alterity has received from The Michael J. Fox Foundation to support the development of ATH434 in PD. ....

Daniel Claassen , Margaret Bradbury , David Finkelstein , Werner Poewe , David Stamler , Mental Health , European Commission , Nonclinical Development , Florey Institute Of Neuroscience , University Innsbruck , Securities Exchange , Michaelj Fox Foundation , Alterity Therapeutics , Michaelj Fox Foundation For Parkinson Research , Pd Research Laboratory , Chief Executive Officer Dr David Stamler , Multiple System Atrophy , Medical University Innsbruck , Vice President , Associate Professor , Vanderbilt University Medical Center , Florey Institute , Alterity Therapeutics Limited , Progressive Supranuclear Palsy , Disease Statistics , System Atrophy ,